Dr. Brentjens on CAR T-Cell Therapy Challenges

Video

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.

CAR T-Cell therapy works well for acute lymphoblastic leukemia (ALL), but does not have as significant of an impact on chronic lymphocytic leukemia (CLL). Determining how to increase the impact of CAR T-Cell therapy for other types of hematologic malignancies is the a challenge investigators should be working to solve, says Brentjens.

Another challenge is determining how to expand CAR T-Cell therapy into other cancers. To do this, targets on the tumor-cell surfaces for each different tumor type must be identified.

Related Videos
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Pat Furlong, BSN, RN
Related Content
© 2024 MJH Life Sciences

All rights reserved.